Programme Thesis
VitaDAO funds decentralized, community-driven longevity research to accelerate the development of therapies that extend human healthspan, leveraging blockchain-based governance and open science principles. It exists to democratize funding for early-stage, high-risk longevity projects that traditional venture capital or grants often overlook, fostering a global community of researchers and token holders.
Selection Criteria
- Scientific merit and novelty of the proposed research
- Alignment with VitaDAO's mission to extend human healthspan
- Open science commitment (preprints, open data, code)
- Feasibility and clarity of the research plan
- Track record of the applicant (publications, patents, platforms)
- Potential for real-world impact and translation
- Community engagement and willingness to participate in DAO governance
- Diversity and inclusion (LMIC, early-career, independent researchers valued)
Past Winners / Cohort Profiles
VitaDAO has funded projects ranging from epigenetic reprogramming (e.g., Turn Biotechnologies) to AI-driven drug discovery for aging. Typical winners are early-stage biotech startups, academic labs, and independent researchers with strong open-science practices. Named examples include projects on NAD+ metabolism, senolytics, and mitochondrial dysfunction. Profiles often feature PhDs or postdocs with a clear longevity focus and a track record of preprints or patents.
Ideal Candidate Fingerprint
The platonic ideal applicant is an early-career researcher with a PhD or equivalent experience, proposing a novel, mechanism-driven intervention for aging or age-related disease. They have a strong publication record (preprints accepted), a clear open-science ethos, and a scalable plan that could benefit from VitaDAO's community and token-based funding. They are eager to engage with the DAO and align their work with longevity biomarkers or healthspan extension.
Recommended Framing
Eniola should frame his CCT model as a novel intervention for neurodegenerative aging, specifically targeting reward-memory encoding that underlies addiction as a chronic, age-accelerating condition. He can highlight how his Bayesian-validated model and open-source platforms (IMPRINT, TOPOLOGIX, GATE) exemplify the open-science, decentralized ethos VitaDAO champions. Emphasize that addiction accelerates biological aging (e.g., via oxidative stress, neuroinflammation), positioning his work as a longevity-relevant therapeutic strategy with strong computational and preclinical validation.
Watch Out
Eniola lacks a PhD or current MSc enrollment, which may be a disadvantage for a programme typically funding postdoctoral or faculty-level researchers. VitaDAO's primary focus is longevity/aging, not addiction per se, so the framing must convincingly link addiction to aging mechanisms. His independent researcher status and LMIC location are strengths but may raise questions about institutional support and access to wet-lab validation.